RE:RE:RE:RE:Aion Grants .15 Stock Options & Management ChangeThere appears to be greater level of confidence in the business plan's future outcome, only the dots have to be connected. ( Tight Lips on management side )
One must read between the lines, draw your own conclusions and trust nobody but yourself.
RE: Dr. Thompson; He is still in the picture and per announcement; Dr. Thompson tendered his resignation to accept a senior bio-medical advisor role with one of Aion Therapeutic's institutional investors which will allow him to continue to support the development of the Company. (Sounds like a takeover or joint venture partnership, time will tell when the MOA is released).
My level of enthusiasm has moved to a higher level as an investor based on what I detect between the lines as the dots are coming together, sometimes patience is a virtue. One key fundamental question is ???. Who are the Aion Therapeutic's
Investors that are keeping Dr. Thompson. ( Are they the group that have been accumulating the stock as pointed out by many of you) Based on the aforementioned information realeased by the company, there must be working on something behind the scenes that will be publicly release soon. ( Yes; this could be big) must you fasten your seat belt.??? Here is the earlier announcement by the Company; The Company also announced the resignation of Dr. James Thompson as President of Aion Therapeutic, effective February 2, 2021. Dr. Thompson tendered his resignation to accept a senior bio-medical advisor role with one of Aion Therapeutic's institutional investors which will allow him to continue to support the development of the Company.
Graham Simmonds, Executive Vice Chair & CEO of Aion Therapeutic, commented, "On behalf of the board and management team, we wish to extend our gratitude to Dr. Thompson for his valuable insight and service to the Company as President and we look forward to working with him in his new capacity."
About Aion Therapeutic Inc.
Aion Therapeutic Inc. (formerly, Osoyoos Cannabis Inc.) has a joint-venture agreement with a private, vertically-integrated licensed producer under the Cannabis Act (Canada) to offer contract tolling extraction services to third-party businesses. Additionally, the Company recently acquired 1196691 B.C. Ltd. d/b/a "PCAI Pharma" (www.pcai.ca) and its wholly-owned subsidiary AI Pharmaceuticals Jamaica Limited, a private corporation incorporated and operating under the laws of Jamaica. The business of AI Pharma involves, research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, the Company is creating a strong international intellectual property portfolio related to their discoveries.
In the name of disclosure I am only a shareholder with an opinion with no ties to anyone.